PedAM
Pediatric Disease Annotations & Medicines
| Disease | portal hypertension |
| Phenotype | C0023895|liver diseases |
| Sentences | 11 |
| PubMedID- 20065573 | Background/aim: esophageal varices (evs) are a serious consequence of portal hypertension in patients with liver diseases. |
| PubMedID- 23123767 | Measuring spp using ultrasound is most simple and minimally invasive, and it might be useful for evaluating portal hypertension in dogs with liver diseases. |
| PubMedID- 21932390 | Targeting angiogenesis in chronic liver diseases with portal hypertension: anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib. |
| PubMedID- 24613858 | Purpose of review: cirrhosis is the result of the progression of necroinflammatory liver diseases leading to fibrosis, portal hypertension, and a catabolic state, which might cause muscle wasting or sarcopenia. |
| PubMedID- 24796378 | Aim: liver fibrosis occurs as a result of several chronic liver diseases and leads to portal hypertension, cirrhosis and liver failure, often requiring liver transplantation. |
| PubMedID- 22662598 | Clinical application of transient elastography in prediction of portal hypertension related complication in patients with chronic liver diseases. |
| PubMedID- 22567478 | Significant morbidity is seen in those patients who develop complications such as end-stage renal diseases, chronic liver diseases with portal hypertension, and cancers associated with schistosomiasis [1–3]. |
| PubMedID- 22973991 | Objectives: transient elastography (te), as a non-invasive method, has been studied for evaluation of portal hypertension in patients with chronic liver diseases (cld) with variable results. |
| PubMedID- 21685145 | Background: a group of non-cirrhotic chronic liver diseases, all with sustained portal hypertension and clinically mistaken as cirrhosis, have been described under various names, apparently because of differences in pathological features. |
| PubMedID- 25590846 | Furthermore, to exclude the effect of cardiovascular factors, patients with confirmed cardiovascular diseases or taking any agents affecting qtc interval before the establishment of achblf were excluded, such as β-blockers, even if it is recommended in patients with portal hypertension associated with chronic liver diseases. |
| PubMedID- 25667596 | Cirrhosis is scarring of the liver and also is the final stage of many chronic liver diseases, leading to portal hypertension and end-stage liver disease [1]. |
Page: 1